Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.
Daniel B ChastainBryan P WhiteDavid A CretellaChristopher M BlandPublished in: The Annals of pharmacotherapy (2017)
Completely sparing carbapenem therapy cannot be justified among patients with ESBL BSIs. Determining the source of infection is critical to identify patients for whom carbapenem-sparing therapy is appropriate.
Keyphrases
- klebsiella pneumoniae
- acinetobacter baumannii
- multidrug resistant
- gram negative
- end stage renal disease
- escherichia coli
- robot assisted
- pseudomonas aeruginosa
- newly diagnosed
- chronic kidney disease
- ejection fraction
- stem cells
- drug resistant
- peritoneal dialysis
- cystic fibrosis
- minimally invasive
- chemotherapy induced